Huang MJ, Kua KE, Teng HC, Tang KS, Weng HW, Huang CS. Risk factors for severe hyperbilirubinemia in neonates. Pediatr Res. 2004 Nov. 56(5):682-9. [Medline].
Christensen RD, Yaish HM. Hemolytic disorders causing severe neonatal hyperbilirubinemia. Clin Perinatol. 2015 Sep. 42 (3):515-27. [Medline].
Woodgate P, Jardine LA. Neonatal jaundice: phototherapy. BMJ Clin Evid. 2015 May 22. 2015:[Medline].
Macias RI, Marin JJ, Serrano MA. Excretion of biliary compounds during intrauterine life. World J Gastroenterol. 2009 Feb 21. 15 (7):817-28. [Medline]. [Full Text].
Yusoff S, Van Rostenberghe H, Yusoff NM, et al. Frequencies of A(TA)7TAA, G71R, and G493R mutations of the UGT1A1 gene in the Malaysian population. Biol Neonate. 2006. 89(3):171-6. [Medline]. [Full Text].
Memon N, Weinberger BI, Hegyi T, Aleksunes LM. Inherited disorders of bilirubin clearance. Pediatr Res. 2015 Nov 23. [Medline].
Watchko JF, Lin Z. Genetics of neonatal jaundice. Stevenson DK, Maisels MJ, Watchko JF. Care of the jaundiced neonate. New York: McGraw-Hill; 2012. 1-27.
Fujiwara R, Maruo Y, Chen S, Tukey RH. Role of extrahepatic UDP-glucuronosyltransferase 1A1: Advances in understanding breast milk-induced neonatal hyperbilirubinemia. Toxicol Appl Pharmacol. 2015 Nov 15. 289 (1):124-32. [Medline].
Hua L, Shi D, Bishop PR, Gosche J, May WL, Nowicki MJ. The role of UGT1A1*28 mutation in jaundiced infants with hypertrophic pyloric stenosis. Pediatr Res. 2005 Nov. 58(5):881-4. [Medline].
Yamamoto A, Nishio H, Waku S, Yokoyama N, Yonetani M, Uetani Y. Gly71Arg mutation of the bilirubin UDP-glucuronosyltransferase 1A1 gene is associated with neonatal hyperbilirubinemia in the Japanese population. Kobe J Med Sci. 2002 Aug. 48(3-4):73-7. [Medline].
Kumral A, Ozkan H, Duman N, Yesilirmak DC, Islekel H, Ozalp Y. Breast milk jaundice correlates with high levels of epidermal growth factor. Pediatr Res. 2009 Aug. 66(2):218-21. [Medline].
Maisels MJ, Newman TB. The epidemiology of neonatal hyperbilirubinemia. Stevenson DK, Maisels MJ, Watchko JF. Care of the jaundiced neonate. New York: McGraw-Hill; 2012. 97-113.
Maisels MJ, Gifford K. Normal serum bilirubin levels in the newborn and the effect of breast- feeding. Pediatrics. 1986 Nov. 78(5):837-43. [Medline].
[Guideline] Atkinson LR, Escobar GJ, Takyama JI, Newman TB. Phototherapy use in jaundiced newborns in a large managed care organization: do clinicians adhere to the guideline?. Pediatrics. 2003. 111:e555. [Medline]. [Full Text].
Slusher TM, Olusaniya BO. Neonatal jaundice in low- and middle-income countries. Stevenson DK, Maisels MJ, Watchko JF. Care of the jaundiced neonate. New York: McGraw-Hill; 2012. 263-73.
Moore LG, Newberry MA, Freeby GM, Crnic LS. Increased incidence of neonatal hyperbilirubinemia at 3,100 m in Colorado. Am J Dis Child. 1984 Feb. 138(2):157-61. [Medline].
Sarici SU, Serdar MA, Korkmaz A, et al. Incidence, course, and prediction of hyperbilirubinemia in near-term and term newborns. Pediatrics. 2004. 113:775-80. [Medline]. [Full Text].
Ebbesen F, Andersson C, Verder H, Grytter C, Pedersen-Bjergaard L, Petersen JR. Extreme hyperbilirubinaemia in term and near-term infants in Denmark. Acta Paediatr. 2005 Jan. 94(1):59-64. [Medline].
Linn S, Schoenbaum SC, Monson RR, Rosner B, Stubblefield PG, Ryan KJ. Epidemiology of neonatal hyperbilirubinemia. Pediatrics. 1985 Apr. 75(4):770-4. [Medline].
Maisels MJ, Newman TB. Prevention, screening and postnatal management of neonatal hyperbilirubinemia. Stevenson DK, Maisels MJ, Watchko JF. Care of the jaundiced neonate. New York: McGraw-Hill; 2012. 175-94.
Slusher TM, Vreman HJ, McLaren DW, Lewison LJ, Brown AK, Stevenson DK. Glucose-6-phosphate dehydrogenase deficiency and carboxyhemoglobin concentrations associated with bilirubin-related morbidity and death in Nigerian infants. J Pediatr. 1995 Jan. 126(1):102-8. [Medline].
Knudsen A. The influence of the reserve albumin concentration and pH on the cephalocaudal progression of jaundice in newborns. Early Hum Dev. 1991 Jan-Feb. 25(1):37-41. [Medline].
Purcell N, Beeby PJ. The influence of skin temperature and skin perfusion on the cephalocaudal progression of jaundice in newborns. J Paediatr Child Health. 2009 Oct. 45(10):582-6. [Medline].
[Guideline] Bhutani VK, Maisels MJ, Stark AR, Buonocore G. Management of jaundice and prevention of severe neonatal hyperbilirubinemia in infants >or=35 weeks gestation. Neonatology. 2008. 94(1):63-7. [Medline].
Bhutani VK, Johnson LH, Maisels MJ, et al. Kernicterus: epidemiological strategies for its prevention through systems-based approaches. J Perinatol. 2004. 24:650-62. [Medline]. [Full Text].
Mishra S, Chawla D, Agarwal R, Deorari AK, Paul VK, Bhutani VK. Transcutaneous bilirubinometry reduces the need for blood sampling in neonates with visible jaundice. Acta Paediatr. 2009 Dec. 98(12):1916-9. [Medline].
Bhutani VK, Gourley GR, Adler S, et al. Noninvasive measurement of total serum bilirubin in a multiracial predischarge newborn population to assess the risk of severe hyperbilirubinemia. Pediatrics. 2000 Aug. 106(2):E17. [Medline]. [Full Text].
Keren R, Tremont K, Luan X, Cnaan A. Visual assessment of jaundice in term and late preterm infants. Arch Dis Child Fetal Neonatal Ed. 2009 Sep. 94(5):F317-22. [Medline].
Riskin A, Tamir A, Kugelman A, Hemo M, Bader D. Is visual assessment of jaundice reliable as a screening tool to detect significant neonatal hyperbilirubinemia?. J Pediatr. 2008 Jun. 152(6):782-7, 787.e1-2. [Medline].
Schutzman DL, Sekhon R, Hundalani S. Hour-specific bilirubin nomogram in infants with ABO incompatibility and direct Coombs-positive results. Arch Pediatr Adolesc Med. 2010 Dec. 164(12):1158-64. [Medline].
Ahlfors CE, Parker AE. Unbound bilirubin concentration is associated with abnormal automated auditory brainstem response for jaundiced newborns. Pediatrics. 2008 May. 121(5):976-8. [Medline].
Mreihil K, Madsen P, Nakstad B, Benth JS, Ebbesen F, Hansen TW. Early formation of bilirubin isomers during phototherapy for neonatal jaundice: effects of single vs. double fluorescent lamps vs. photodiodes. Pediatr Res. 2015 Jul. 78 (1):56-62. [Medline].
Vandborg PK, Hansen BM, Greisen G, Ebbesen F. Dose-response relationship of phototherapy for hyperbilirubinemia. Pediatrics. 2012 Aug. 130(2):e352-7. [Medline].
Kumar P, Chawla D, Deorari A. Light-emitting diode phototherapy for unconjugated hyperbilirubinaemia in neonates. Cochrane Database Syst Rev. 2011 Dec 7. 12:CD007969. [Medline].
Tridente A, De Luca D. Efficacy of light-emitting diode versus other light sources for treatment of neonatal hyperbilirubinemia: a systematic review and meta-analysis. Acta Paediatr. 2012 May. 101(5):458-65. [Medline].
Gottstein R, Cooke RW. Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. 2003 Jan. 88(1):F6-10. [Medline]. [Full Text].
Rubo J, Albrecht K, Lasch P, et al. High-dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. J Pediatr. 1992 Jul. 121(1):93-7. [Medline].
Huizing K, Roislien J, Hansen T. Intravenous immune globulin reduces the need for exchange transfusions in Rhesus and AB0 incompatibility. Acta Paediatr. 2008 Oct. 97(10):1362-5. [Medline].
Hansen TW. Therapeutic approaches to neonatal jaundice: an international survey. Clin Pediatr (Phila). 1996 Jun. 35(6):309-16. [Medline].
[Guideline] American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004 Jul. 114(1):297-316. [Medline]. [Full Text].
Maisels MJ, Watchko JF, Bhutani VK, Stevenson DK. An approach to the management of hyperbilirubinemia in the preterm infant less than 35 weeks of gestation. J Perinatol. 2012 Sep. 32(9):660-4. [Medline].
Morris BH, Oh W, Tyson JE, et al. Aggressive vs. conservative phototherapy for infants with extremely low birth weight. N Engl J Med. 2008 Oct 30. 359(18):1885-96. [Medline]. [Full Text].
Hintz SR, Stevenson DK, Yao Q, et al. Is phototherapy exposure associated with better or worse outcomes in 501- to 1000-g-birth-weight infants?. Acta Paediatr. 2011 Jul. 100(7):960-965. [Medline].
Tyson JE, Pedroza C, Langer J, et al. Does aggressive phototherapy increase mortality while decreasing profound impairment among the smallest and sickest newborns?. J Perinatol. 2012 Sep. 32(9):677-84. [Medline]. [Full Text].
Hansen TW. Let there be light-but should there be less?. J Perinatol. 2012 Sep. 32(9):649-51. [Medline].
Madan JC, Kendrick D, Hagadorn JI, Frantz ID 3rd. Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome. Pediatrics. 2009 Feb. 123(2):674-81. [Medline].
Johnson L, Bhutani VK, Karp K, Sivieri EM, Shapiro SM. Clinical report from the pilot USA Kernicterus Registry (1992 to 2004). J Perinatol. 2009 Feb. 29 Suppl 1:S25-45. [Medline].
Hansen TW, Nietsch L, Norman E, et al. Reversibility of acute intermediate phase bilirubin encephalopathy. Acta Paediatr. 2009 Oct. 98(10):1689-94. [Medline].
Calado CS, Pereira AG, Santos VN, Castro MJ, Maio JF. What brings newborns to the emergency department?: a 1-year study. Pediatr Emerg Care. 2009 Apr. 25(4):244-8. [Medline].
Newman TB, Liljestrand P, Escobar GJ. Combining clinical risk factors with serum bilirubin levels to predict hyperbilirubinemia in newborns. Arch Pediatr Adolesc Med. 2005 Feb. 159(2):113-9. [Medline].
Bhutani VK, Johnson LH, Keren R. Diagnosis and management of hyperbilirubinemia in the term neonate: for a safer first week. Pediatr Clin North Am. 2004 Aug. 51(4):843-61, vii. [Medline].
Eggert LD, Wiedmeier SE, Wilson J, Christensen RD. The effect of instituting a prehospital-discharge newborn bilirubin screening program in an 18-hospital health system. Pediatrics. 2006 May. 117(5):e855-62. [Medline].
Paul IM, Phillips TA, Widome MD, Hollenbeak CS. Cost-effectiveness of postnatal home nursing visits for prevention of hospital care for jaundice and dehydration. Pediatrics. 2004 Oct. 114(4):1015-22. [Medline].
Suresh GK, Clark RE. Cost-effectiveness of strategies that are intended to prevent kernicterus in newborn infants. Pediatrics. 2004 Oct. 114(4):917-24. [Medline].
[Guideline] Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF. Hyperbilirubinemia in the newborn infant > or =35 weeks' gestation: an update with clarifications. Pediatrics. 2009 Oct. 124(4):1193-8. [Medline].
Buiter HD, Dijkstra SS, Oude Elferink RF, Bijster P, Woltil HA, Verkade HJ. Neonatal jaundice and stool production in breast- or formula-fed term infants. Eur J Pediatr. 2008 May. 167(5):501-7. [Medline].
Cremer RJ, Perryman PW. Influence of light on the hyperbilirubinemia of infants. Lancet. 1958. 1:1094-7.
Gourley GR, Li Z, Kreamer BL, Kosorok MR. A controlled, randomized, double-blind trial of prophylaxis against jaundice among breastfed newborns. Pediatrics. 2005 Aug. 116(2):385-91. [Medline]. [Full Text].
Grohmann K, Roser M, Rolinski B, et al. Bilirubin measurement for neonates: comparison of 9 frequently used methods. Pediatrics. 2006 Apr. 117(4):1174-83. [Medline].
Hansen TW. Acute management of extreme neonatal jaundice--the potential benefits of intensified phototherapy and interruption of enterohepatic bilirubin circulation. Acta Paediatr. 1997 Aug. 86(8):843-6. [Medline].
Hansen TW. Recent advances in the pharmacotherapy for hyperbilirubinaemia in the neonate. Expert Opin Pharmacother. 2003. 4(11):1939-48. [Medline]. [Full Text].
Hansen TW, Allen JW. Hemolytic anemia does not increase entry into, nor alter rate of clearance of bilirubin from rat brain. Biol Neonate. 1996. 69(4):268-74. [Medline].
Hart C, Cameron R. The importance of irradiance and area in neonatal phototherapy. Arch Dis Child Fetal Neonatal Ed. 2005. 90:F437-F440. [Medline]. [Full Text].
Hervieux, J. De l'ictere des nouveau-nes. Paris: These med. 1847.
Ho HT, Ng TK, Tsui KC, Lo YC. Evaluation of a new transcutaneous bilirubinometer in Chinese newborns. Arch Dis Child Fetal Neonatal Ed. 2006 Nov. 91(6):F434-8. [Medline].
Kaplan M, Bromiker R, Schimmel MS, Algur N, Hammerman C. Evaluation of discharge management in the prediction of hyperbilirubinemia: the Jerusalem experience. J Pediatr. 2007 Apr. 150(4):412-7. [Medline].
Kaplan M, Renbaum P, Vreman HJ, Wong RJ, Levy-Lahad E, Hammerman C. (TA)n UGT 1A1 Promoter Polymorphism: A Crucial Factor in the Pathophysiology of Jaundice in G-6-PD Deficient Neonates. Pediatr Res. 2007 Apr 5. [Medline].
Kaplan M, Shchors I, Algur N, Bromiker R, Schimmel MS, Hammerman C. Visual screening versus transcutaneous bilirubinometry for predischarge jaundice assessment. Acta Paediatr. 2008 Jun. 97(6):759-63. [Medline].
Keren R, Bhutani VK, Luan X, Nihtianova S, Cnaan A, Schwartz JS. Identifying newborns at risk of significant hyperbilirubinaemia: a comparison of two recommended approaches. Arch Dis Child. 2005 Apr. 90(4):415-21. [Medline].
Kuzniewicz MW, Escobar GJ, Wi S, Liljestrand P, McCulloch C, Newman TB. Risk factors for severe hyperbilirubinemia among infants with borderline bilirubin levels: a nested case-control study. J Pediatr. 2008 Aug. 153(2):234-40. [Medline].
Lin Z, Fontaine J, Watchko JF. Coexpression of gene polymorphisms involved in bilirubin production and metabolism. Pediatrics. 2008 Jul. 122(1):e156-62. [Medline].
Maisels MJ, McDonagh AF. Phototherapy for neonatal jaundice. N Engl J Med. 2008 Feb 28. 358(9):920-8. [Medline].
Maisels MJ, Newman TB, Watchko JF. Effect of predischarge bilirubin screening on subsequent hyperbilirubinemia. Pediatrics. 2006 Oct. 118(4):1796; author reply 1976-7. [Medline].
Muslu N, Dogruer ZN, Eskandari G, Atici A, Kul S, Atik U. Are glutathione S-transferase gene polymorphisms linked to neonatal jaundice?. Eur J Pediatr. 2008 Jan. 167(1):57-61. [Medline].
Newman TB, Liljestrand P, Jeremy RJ, Ferriero DM, Wu YW, Hudes ES. Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more. N Engl J Med. 2006 May 4. 354(18):1889-900. [Medline].
Ostrow JD, Jandl JH, Schmid R. The formation of bilirubin from hemoglobin in vivo. J Clin Invest. 1962. 41:1628-37.
Seidman DS, Moise J, Ergaz Z. A new blue light-emitting phototherapy device: a prospective randomized controlled study. J Pediatr. 2000. 136:771-4. [Medline]. [Full Text].
Smitherman H, Stark AR, Bhutan VK. Early recognition of neonatal hyperbilirubinemia and its emergent management. Semin Fetal Neonatal Med. 2006 Jun. 11(3):214-24. [Medline].
Sun G, Wu M, Cao J, Du L. Cord blood bilirubin level in relation to bilirubin UDP-glucuronosyltransferase gene missense allele in Chinese neonates. Acta Paediatr. 2007 Nov. 96(11):1622-5. [Medline].
Watchko JF. Vigintiphobia revisited. Pediatrics. 2005 Jun. 115(6):1747-53. [Medline]. [Full Text].
Taylor JA, Stout JW, de Greef L, et al. Use of a smartphone app to assess neonatal jaundice. Pediatrics. 2017 Sep. 140 (3):[Medline].
Olusanya BO, Slusher TM, Imosemi DO, Emokpae AA. Maternal detection of neonatal jaundice during birth hospitalization using a novel two-color icterometer. PLoS One. 2017. 12 (8):e0183882. [Medline]. [Full Text].
Chen Z, Zhang L, Zeng L, et al. Probiotics supplementation therapy for pathological neonatal jaundice: a systematic review and meta-analysis. Front Pharmacol. 2017. 8:432. [Medline]. [Full Text].
Yang L, Wu, Wang B, Bu X, Tang J. The influence of zinc sulfate on neonatal jaundice: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2017 Apr 24. 1-7. [Medline].
Barekatain B, Badiea Z, Hoseini N. The effect of head covering in prevention of phototherapy-induced hypocalcemia in icterus newborns with gestational age less than 35 weeks. Adv Biomed Res. 2016. 5:176. [Medline]. [Full Text].
Chaudhari H, Goyal S, Patil C. Neonates with sickle cell disease are vulnerable to blue light phototherapy-induced oxidative stress and proinflammatory cytokine elevations. Med Hypotheses. 2016 Nov. 96:78-82. [Medline].
Christensen RD, Agarwal AM, Yaish HM, Reading NS, O'Brien EA, Prchal JT. Three novel spectrin variants in jaundiced neonates. Clin Pediatr (Phila). 2018 Jan. 57 (1):19-26. [Medline].
Keahey PA, Simeral ML, Schroder KJ, et al. Point-of-care device to diagnose and monitor neonatal jaundice in low-resource settings. Proc Natl Acad Sci U S A. 2017 Dec 19. 114 (51):E10965-E10971. [Medline].
Mitra S, Rennie J. Neonatal jaundice: aetiology, diagnosis and treatment. Br J Hosp Med (Lond). 2017 Dec 2. 78 (12):699-704. [Medline].
This is a jaundiced, 4 day old, 3.1 kg, appropriate for gestational age (AGA) Asian female infant born at term to a 25 year old A+ primiparous woman with gestational diabetes. The pregnancy was otherwise uneventful. Labor was augmented with Pitocin. The baby was discharged home on day of life 2 at which time her weight was down 4% from birth weight and she had mild facial jaundice. In the hospital, she was breast fed every 3 hours and had 2 wet diapers and one meconium stool over a 24 hour period. On day 3, her parents gave her water on two occasions as she appeared hungry despite regular and frequent breast feeding attempts. In addition, they noted an increase in the degree of jaundice, but failed to address it after being reassured by family members that jaundice is common. They also had an appointment to see their pediatrician the following day. In the office, on day 4, mother reports that she is breastfeeding the baby every three hours and that there have been 2 wet diapers per day. The urine is described as dark yellow in color and the stools appear dark green.
Exam: VS T 37.8, P 162, RR 55, BP 63/45. Weight 2.7 kg (25%ile), length 50 cm (75%ile), head circumference 34 cm (75%ile). The infant is jaundiced and irritable. The anterior fontanel is slightly sunken, the oral mucosa is tacky, and there is jaundice to the lower extremities. No cephalohematoma or bruising is present. The sclera of both eyes are icteric. Muscle tone and activity are normal. The remainder of the physical exam is normal.
The total bilirubin is 20 mg% with a direct fraction of 0.7 mg%. She is admitted to the hospital for phototherapy, supplementary formula feedings, and lactation consultation. By the following day, the bilirubin has decreased to 12 mg% and she is discharged home on breast milk feedings. She baby is scheduled for follow-up with both the pediatrician and the lactation consultant.
A 4 day old, 36 week gestation male presents to his primary care physician with worsening jaundice. The maternal blood type is 0+. He was discharged home on day 2 of life after successfully breastfeeding for a 24 hour period. At the time of discharge, his physical exam was remarkable for mild jaundice and a cephalohematoma. At today's visit there is an 8% weight loss from birth and a history of "fair" urine output and yellow stools. He is markedly jaundiced and has a resolving cephalohematoma. Other physical exam findings are remarkable for a normal cry, flat anterior fontanelle, moist oral mucosa and a normal neurologic examination. The total bilirubin is 27 mg% with a direct fraction of 1 mg%. He is admitted to the hospital where phototherapy is initiated. His blood type is A+ with a positive direct Coombs. The hematocrit is 42% with a reticulocyte count of 12% and the pathologist identifies spherocytes on the blood smear. The G6PD is pending. After 12 hours of phototherapy, a repeat bilirubin is 25 mg%. The G6PD is normal. The decision is made to perform a double volume exchange transfusion. The infant remains on phototherapy for an additional 2 days and is discharged home after being off phototherapy for 1 day. The serum bilirubin on the day of discharge is 12 mg% and he passes an auditory brainstem response test.
More than 50% of term neonates become jaundiced (1). In this community (Hawaii), hyperbilirubinemia is one of the major reasons for re-hospitalization within the first two weeks of life. The primary reason for the level of concern over jaundice and hyperbilirubinemia in the newborn is the association of hyperbilirubinemia with kernicterus, which is a rare, but devastating neurologic complication of hyperbilirubinemia. Kernicterus can occur without signs and symptoms (2), but acute kernicterus in term babies is usually characterized by changes in muscle tone, drowsiness, poor feeding, a high pitched cry, apnea, possible seizures, fever, and death (3). Neurologic sequelae include dystonia and athetosis, upward gaze abnormalities, sensorineural hearing loss, intellectual deficits and tooth enamel dysplasia (3). In term patients, the MRI has increased signal intensity in the globus pallidus on T2 images (2). Although kernicterus is rare, it is potentially preventable and it is being seen with increasing frequency. This has prompted a recent Joint Commission on Accreditation of Healthcare Organizations Sentinel Event Alert (4).
The assessment and management of hyperbilirubinemia can be confusing. For instance, a bilirubin of 11 mg% has a different significance under different circumstances. It would be considered physiologic (not pathologic) in a 4 day old term breast fed baby, while the same level would be pathologic on day 1. A serum bilirubin of 11 mg% would also be concerning in a sick, two day old, 27 week gestation premature infant. Clinical decision-making is based on serum bilirubin values which are not directly reflective of risk for neurotoxicity (3). In an attempt to assist physicians with this common problem, the AAP released a practice parameter in 1994 on the Management of Hyperbilirubinemia in the Healthy Term Newborn (5). According to the commentary from the AAP Subcommittee on Neonatal Hyperbilirubinemia in 2001, this practice parameter is currently being revised (6).
Hyperbilirubinemia is more common in neonates due to the shortened life span of their red blood cells, declining hematocrit, immature liver uptake and conjugation of bilirubin, and increased intestinal reabsorption of bilirubin. Hemoglobin breakdown releases iron, carbon monoxide, and biliverdin. The latter is reduced to bilirubin, which enters the liver. Uridine diphosphate glucuronyltransferase (UDPGT) conjugates bilirubin into an excretable form. Intestinal bacteria can deconjugate bilirubin allowing for reabsorption of bilirubin into the circulation. This increased enterohepatic circulation occurs particularly in preterm neonates with diminished stool passage. In Asians, a variant in the UDPGT has been associated with hyperbilirubinemia.
Infants with red blood cell membrane G6PD (glucose-6-phosphate dehydrogenase) deficiency have a tendency for hemolysis and hyperbilirubinemia. In G6PD deficiency, hyperbilirubinemia can occur despite minimal evidence for hemolysis. Also, decreased conjugation of bilirubin has been described in G6PD deficiency.
Most unconjugated bilirubin is bound to albumin, but free unconjugated bilirubin (a form unbound to albumin) can enter the brain (i.e., it can cross the blood brain barrier). Sulfonamides are contraindicated in the neonatal period because they displace bilirubin from albumin. Conditions that disrupt the integrity of the blood brain barrier, such as infection (e.g., sepsis, meningitis, congenital viral infections), acidosis, prematurity, and hyperosmolarity, place the infant at increased risk for kernicterus. Hemolytic causes of hyperbilirubinemia (Rh incompatibility and G6PD deficiency) have higher risks of kernicterus compared to other causes of jaundice at comparable bilirubin levels.
Bilirubin may be the toxic substances responsible for kernicterus, but this is not a certainty. Very high bilirubin levels (in the 30 mg% range) most often do not result in kernicterus if no hemolytic disease is present. However, bilirubins in the 20 mg% range due to Rh incompatibility or G6PD deficiency, often result in kernicterus. The paradox that a very high bilirubin due to non-hemolytic causes has a lower kernicterus risk while a moderately high bilirubin due to Rh incompatibility or G6PD deficiency has a higher kernicterus risk, suggests that bilirubin itself may not be the direct cause of kernicterus. Bilirubin may only be a marker of the true toxic substance that causes kernicterus. This phenomenon may explain why the risk of kernicterus is not determined by bilirubin levels alone.
Jaundice can be detected clinically with tactile blanching of the skin revealing an underlying yellow color. The examination should be done in a well-lit, neutral light. Jaundice usually begins on the face and progresses caudally. The presence of scleral icterus should be assessed. Generally, the farther the jaundice progresses down the body, the higher the total serum bilirubin (3). The more intense the color (which can approach a yellow-orange) also suggests a higher total serum bilirubin. Jaundice may be clinically detected with a total serum bilirubin of 5 mg%. The presence of jaundice in particularly dark skinned newborns can be difficult to assess. Any time there is uncertainty, the recommendation is to check a total serum or transcutaneous bilirubin. Universal screening has been recently recommended, perhaps simultaneously with the newborn screen. If a patient is under phototherapy, jaundice is difficult to visually assess because phototherapy preferentially reduces bilirubin concentrations near the skin. If assessing a patient under phototherapy, jaundice severity is best determined by examining unexposed sites (e.g., under the eye shield) and phototherapy should be interrupted during the exam. If the skin is green or bronze colored, this suggests an elevated direct (conjugated) bilirubin fraction, so a fractionated bilirubin should be obtained. The patient should also be assessed for pallor, plethora and hepatosplenomegaly.
It is essential to distinguish whether the jaundice is physiologic or pathologic. Jaundice noted within the first 24 hours is pathologic and a total serum bilirubin should be drawn. Early jaundice is usually related to hemolysis, infection, drug effect, neonatal hepatitis or liver enzyme defects (e.g., Crigler-Najjar-deficiency of UDPGT) (7). A total bilirubin greater than 17 mg% in a full term neonate is pathologic (2). Jaundice that persists beyond 2 weeks should be evaluated beginning with a fractionated bilirubin (5). Direct hyperbilirubinemia is also considered pathologic, (i.e., direct bilirubin >1.5-2 mg% or > 20% of the total bilirubin) (8).
Direct (conjugated) hyperbilirubinemia cases are relatively uncommon. The differential diagnosis includes neonatal hepatitis, biliary atresia, sepsis, metabolic disorders (e.g., galactosemia), and hepatotoxicity from hyperalimentation. A detailed discussion of direct hyperbilirubinemia is beyond the scope of this chapter. One of the principal diagnoses to exclude is biliary atresia which is associated with dark urine or light colored stool. Early surgical intervention done prior to 2 months of age reduces mortality and the probability of future liver transplantation (refer to the chapter on biliary atresia).
Indirect (unconjugated) hyperbilirubinemia, is more common and presents a risk for kernicterus. The most common causes of indirect hyperbilirubinemia are physiologic, breast milk, breast feeding with a large postnatal weight loss (3), ABO incompatibility, cephalohematoma, bruising, G6PD deficiency, and East Asian ethnicity. Of these, G6PD deficiency poses a higher risk of kernicterus, but ABO incompatibility is a more common reason for exchange transfusion. Rh incompatibility is less common, but represents a high risk of kernicterus. Breastfeeding jaundice is related to inadequate intake by the newborn (i.e., components of poor feeding and dehydration are contributory). Breast milk jaundice (i.e., due to breast milk itself) has its onset later than breastfeeding jaundice. It is related to increased enterohepatic circulation and is relatively uncommon. Uncommon causes of indirect hyperbilirubinemia include other RBC membrane defects (e.g., hereditary spherocytosis) and hemoglobinopathies. In the pilot kernicterus registry, 31% of the cases were idiopathic (no identified cause), approximately equal to the incidence associated with G6PD deficiency (3).
A rise in bilirubin of greater than 0.5 mg% per hour and failure to control hyperbilirubinemia despite phototherapy are suggestive of hemolytic disease. ABO incompatibility occurs in approximately 20% to 25% of pregnancies of which significant hemolysis occurs in 10%. G6PD deficiency (X-linked recessive) occurs in African, Mediterranean, and Southeast Asian ethnic groups. In our community, some pediatricians routinely screen for G6PD in males delivered to mothers of high risk ethnic groups (e.g., Filipino).
Prenatal testing includes maternal blood typing and screening for antibodies to major RBC antigens (1). Rh incompatibility occurs with an Rh negative mother (usually not a primigravida) and an Rh positive baby. The routine use of RhoGAM at 28 weeks gestation and following delivery or pregnancy termination is generally effective in preventing maternal Rh sensitization (i.e., the production of anti-Rh antibodies by the mother). An adequate amount of RhoGAM must be given to neutralize the amount of Rh Ag or the volume of blood from a feto-maternal transfusion. Thus, the incidence of Rh isoimmunization and Rh incompatibility is uncommon. The Rh antigen is markedly more antigenic than the A or B antigen. In situations where the maternal blood type and antibody screening results are unknown, an Rh and Coombs test should be performed on the baby's blood (1).
In ABO incompatibility, the mother's blood type is O. More commonly, the babies blood type is A rather than B. Hemolysis in ABO isoimmunization usually has a positive direct antiglobulin testing (DAT), also known as a direct Coombs test. Clinically significant hemolysis is associated with a decreasing hemoglobin, hematocrit and an elevated reticulocyte count. Due to phagocytic removal of antibody and portions of the RBC membrane, the smear in ABO incompatibility may have spherocytes, mimicking spherocytosis. Therefore, a CBC with differential, reticulocyte count and a smear should be requested with suspected hemolysis. Nucleated RBCs may also be present with more severe causes of hemolysis, but is classically associated with Rh incompatibility.
If the baby is at risk for G6PD deficiency or other hemolytic diseases, appropriate testing should be done. When a G6PD level is obtained, it is important to realize that false negatives may occur in the face of active hemolysis because G6PD is increased in nucleated red blood cells.
An evaluation should be done for newborns with feeding intolerance, behavioral changes, hepatosplenomegaly, excessive weight loss, and instability of vital signs regardless of clinical detection of jaundice. Urine that is positive for reducing substances, but negative for glucose is suggestive of galactosemia. Galactosemia, a cause of direct hyperbilirubinemia, is one of the over 30 metabolic disorders included in the expanded newborn screen.
Educating parents about proper infant feeding practices (both breast and bottle), detecting their infant's hydration status, observing changes in behavior, and how to detect and report worsening jaundice, are extremely important anticipatory guidance measures. Parents should also be counseled that jaundice is common, but in rare instances, it can lead to severe morbidity and mortality which is largely preventable. At follow-up, the primary care physician should document the presence/absence of jaundice and/or the serum bilirubin level. The pediatrician's goal is to discharge a functional maternal-infant dyad with early follow up (in 1-2 days) if the infant is discharged from the hospital at less than 48 hours of age. If certain risk factors exist such as blood group incompatibility or prematurity, or if early follow-up cannot be scheduled, discharge should be delayed until after the infant has been monitored for an appropriate period of time. Some of the patients with kernicterus had a bilirubin of less than 25 mg% and did not have predictable risk factors (9). Potential separation of the parent and newborn needs to be minimized and weighed against the risks of hyperbilirubinemia complications. In this community, most mothers are discharged within 48 hours of a vaginal delivery and 3-4 days post C-section. Discharging the mother prior to the newborn can affect bonding and breastfeeding. This needs to be weighed against the risk for significant hyperbilirubinemia and compliance with follow up.
The clinician should be responsive to parents who are concerned about their child's degree of jaundice, feeding frequency or volume, drowsiness, and/or irritability (3). Caution should be used when sending patients home while awaiting lab results. Never presume that a lab value is falsely elevated. Parents should also be counseled to seek medical attention for jaundice that persists beyond 2 weeks of age.
Bhutani developed an hour specific bilirubin nomogram in healthy term and near term newborns with a negative direct Coombs (12). The patient population consisted of term and near-term appropriate for gestational age (AGA) newborns. Total serum bilirubins (TSB) of greater than or equal to 8 mg% at 24 hours, greater than or equal to 14 mg% at 48 hours, and greater than or equal to 16 mg% at 72 hours were above the 95th percentile. A TSB of greater than or equal to 17 mg% during the first week of life was above the 95th percentile. This group is at higher risk for bilirubin-induced neurologic dysfunction (BIND), including kernicterus. Bhutani advocates universal bilirubin screening with early follow up to also catch neonates who may move up from the lower percentiles.
The 1994 AAP Practice parameter (5) is an appropriate guideline for managing jaundice in the healthy term newborn without hemolysis. The guideline has age-based recommendations for therapy. At 25 to 48 hours, phototherapy is recommended at a bilirubin of greater than or equal to 15 mg%. At 49 to 72 hours, the threshold increases to 18 mg%. From greater than 72 hours, the threshold is 20 mg%. If G6PD deficiency or other kernicterus risk factors are present, it is advisable to have a lower threshold to begin phototherapy. The AAP Practice parameter also contains recommendations for exchange transfusion. Table 1 below describes hyperbilirubinemia treatment guidelines for preterm infants. Table 2 below describes hyperbilirubinemia treatment guidelines for term infants.
Table 1 - Suggested Maximum Indirect Serum Bilirubin Concentrations (mg%) in Preterm Infants (10)
For table 1 above, phototherapy is usually started at 50% to 70% of the maximum indirect levels. If values greatly exceed this level, if phototherapy is unsuccessful in reducing the maximum bilirubin level, or if there are signs of kernicterus, exchange transfusion is indicated. *Complicated cases include those associated with perinatal asphyxia, acidosis, hypoxia, hypothermia, hypoalbuminemia, meningitis, intraventricular hemorrhage, hemolysis, hypoglycemia, or signs of kernicterus (10).
Table 2 - Treatment Strategies for Indirect Hyperbilirubinemia in Healthy Term Infants Without Hemolysis (10)
If the initial bilirubin on presentation is high, intense phototherapy should be initiated and preparation made for exchange transfusion. If the phototherapy fails to reduce the bilirubin level to the levels noted on the column to the right (table 2), an exchange transfusion should be initiated. Intensive phototherapy usually reduces serum bilirubin levels 1 to 2 mg% in 4 to 6 hours. This is often done with IV fluid administration at 1 to 1.5 times maintenance and oral alimentation should continue (10).
Jaundice in the 1st 24 hours of life is not seen in " healthy" infants. Hyperbilirubinemia of this degree noted in the 24-48 hours line of table 2, is unusual and should suggest hemolysis, concealed hemorrhage, or causes of conjugated (direct) hyperbilirubinemia (10).
Jaundice suddenly appearing in the second week of life or continuing beyond the second week of life with significant hyperbilirubinemia levels to warrant therapy should be investigated in detail, as it most probably is due to a serious underlying cause such as biliary atresia, galactosemia, hypothyroidism, or neonatal hepatitis (10).
Supplementing feeds with water or dextrose has been associated with higher bilirubin levels. Use of metalloporphyrins which inhibit bilirubin production has been limited to study trials in newborns. The mainstay of treatment is phototherapy with a wavelength of 450 nm. It induces photoisomerization of bilirubin, forming lumirubin which is water soluble and excreted in the urine. Phototherapy is generally delivered by fluorescent lights, spot lights, or fiberoptics, the latter generating less heat. Unless there is a high risk for an exchange transfusion, phototherapy can usually be discontinued for an hour to allow for neonatal care. Discontinuation of phototherapy in a term baby without hemolysis generally is not associated with rebound hyperbilirubinemia, i.e., a significant increase in bilirubin.
Although phototherapy may be commonly thought of to prevent kernicterus, this is less than accurate, since if the patient is at significant risk of kernicterus, an exchange transfusion should be done. Phototherapy's major role is to avoid an exchange transfusion. By implementing phototherapy, the belief is that this will reduce the likelihood that bilirubin levels will reach these exchange transfusion levels, thus avoiding an exchange transfusion.
In term neonates with hemolytic disease, if the bilirubin approaches 20 mg% despite medical management, informed consent should be obtained for an exchange transfusion. In preterm neonates less than 37 weeks gestation, most neonatologists will await serum bilirubin levels of 15-20 mg% before considering an exchange (11). Exchange transfusion removes bilirubin and antibodies causing hemolysis. Twice the patient's blood volume is exchanged (i.e., double volume exchange) while monitoring cardiovascular stability. Risk factors include those related to catheters, electrolyte imbalance and blood products superimposed onto preexisting medical problems. Thrombocytopenia is common. Necrotizing enterocolitis, graft versus host disease, and death have also been reported as complications of exchange transfusion.
Does phototherapy reduce the need for an exchange transfusion? In ABO incompatibility, prophylactic phototherapy was not shown to be superior to no therapy at all in this regard (13). However, phototherapy intensities have increased since the time of that study and anecdotally, it appears that fewer exchange transfusions are being done, possibly due to more routine use of phototherapy. Additionally, phototherapy appears to be harmless, so its utilization is reasonable to treat moderately high bilirubin levels.
Although extreme bilirubin levels are associated with kernicterus, the adverse effects of moderate hyperbilirubinemia may be more difficult to identify. For example, subclinical adverse effects, learning disabilities or behavioral disorders would be more difficult to causally link to moderate hyperbilirubinemia, since this would only be manifested in later childhood.
Most cases of hyperbilirubinemia resolve without sequelae. However, there may be impairment of auditory nerve conduction (2). After significant hyperbilirubinemia, the patient should undergo auditory brainstem response testing (6).
1. Which of the following factors leads to neonatal hyperbilirubinemia?
. . . . . a. Shortened neonatal red cell life span.
. . . . . b. Impaired excretion of unconjugated bilirubin.
. . . . . c. Limited conjugation of bilirubin in the liver.
. . . . . d. Increased enterohepatic circulation.
. . . . . e. All of the above.
2. True/False: Hemoglobin degradation results in the formation of biliverdin and carbon monoxide.
3. A total serum bilirubin >17 mg% in a term neonate is:
. . . . . a. physiologic
. . . . . b. pathologic
4. In G6PD deficiency, there is hyperbilirubinemia on the basis of:
. . . . . a. hemolysis
. . . . . b. decreased conjugation
. . . . . c. both
. . . . . d. neither
5. True/False: In Asians, a variant in UDPGT is associated with neonatal hyperbilirubinemia.
6. True/False: Systemic sulfonamide medications are avoided in the newborn because they displace bilirubin from albumin and increase free bilirubin.
7. True/False: Breast milk jaundice is more common than breast feeding jaundice.
8. True/False: Supplementation of breast feeding with water or dextrose lowers the serum bilirubin.
9. True/False: Discontinuation of phototherapy in a healthy, term neonate is usually associated with rebound hyperbilirubinemia.
10. Which of the following factors should be strongly considered in determining whether an exchange transfusion is indicated in a term neonate with an indirect bilirubin of 21 mg%.
. . . . . a. Age of the neonate (time since birth).
. . . . . b. Whether the cause is hemolytic or non-hemolytic.
. . . . . c. The presence of other clinical factors such as intraventricular hemorrhage or meningitis.
. . . . . d. All of the above.
. . . . . e. None of the above.
1. Nazarian LF. Personal Reflections on the AAP Practice Parameter on Management of Hyperbilirubinemia in the Healthy Term Newborn. Pediatr Rev 1998;19(3):75-77.
2. Dennery PA, Seidman DS, Stevenson DK. Neonatal Hyperbilirubinemia. N Engl J Med 2001;344(8):581-590.
3. Johnson LH, Bhutani VK, Brown AK. System-based Approach to Management of Neonatal Jaundice and Prevention of Kernicterus. J Pediatr 2002;140(4):396-403.
4. JCAHO Sentinel Event Alert: Kernicterus Threatens Healthy Newborns. JCAHO website, 2001. http://www.jcaho.org/about+us/news+letters/sentinel+event+alert/sea_18.htm 5. American Academy of Pediatrics. Practice Parameter: Management of Hyperbilirubinemia in the Healthy Term Newborn. Pediatrics 1994;94(4):558-565.
6. AAP Subcommittee on Neonatal Hyperbilirubinemia: Neonatal Jaundice and Kernicterus. Pediatrics 2001;108(3):763-765.
7. Jain SK. Index of suspicion. Case 3. Diagnosis: jaundice. Pediatr Rev 2001;22(8):271-276.
8. Bisgard L. Visual diagnosis: a 10-week-old infant who has jaundice. Pediatr Rev 2001;22(12):408-412.
9. Poland RL. Preventing kernicterus: almost there. J Pediatr 2002;140(4):385-386.
10. Stoll BJ, Kliegman RM. Chapter 98.3. Jaundice and Hyperbilirubinemia in the Newborn. In: Behrman RE, Kliegman RM, Jenson HB (eds.). Nelson Textbook of Pediatrics, 16th edition. 2000, Philadelphia: WB Saunders, pp. 513-517.
11. Chapter 8. Neonatal Complications. In: American Academy of Pediatrics and American College of Obstetricians and Gynecologists. Guidelines for Perinatal Care, 5th edition. 2002, Elk Grove Village, IL: AAP, pp. 239-240.
12. Bhutani VK. Predictive Ability of a Predischarge Hour-specific Serum Bilirubin for Subsequent Significant Hyperbilirubinemia in Healthy Term and Near Term Newborns. Pediatrics 1999;103(1):6-14
13. Maurer HM, Kirkpatrick BV, McWilliams NB, et al. Phototherapy for Hyperbilirubinemia of Hemolytic Disease of the Newborn. Pediatrics 1985;75(2-Supp):407-412.
Answers to questions
1.e, 2.True, 3.b, 4.c, 5.True, 6.True, 7.False, 8.False, 9.False, 10.d